|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. n-Butyl acetate, chemical structure of, 93 C Canadian Study, of Gulf War veterans, 544 Cancer overview, 98–101 and insecticide literature, 99–100 and solvent literature, 156–157 toxicity and carcinogenicity, of insecticides, 100–101, 159 toxicity and carcinogenicity, of solvents, 157 Cancers and exposure to insecticides, 98–155 adult leukemia, 134–139 bone cancer, 110–111 brain and CNS tumors, 121–123 childhood cancer, 139–146 female reproductive cancers, 114–117 gastrointestinal tract cancers, 102–105 hepatobiliary cancers, 105–107 Hodgkin’s disease, 130–131 lung cancer, 107–110 multiple myeloma, 132–134 non-Hodgkin’s lymphoma, 123–130 oral, nasal, and laryngeal cancers, 101–102 skin cancer, 112–114 soft tissue sarcoma, 111–112 urologic cancers, 117–120 Cancers and exposure to organic solvents, 156–349 bone cancer, 224–225 brain and CNS cancers, 272–282 breast cancer, 230–236 childhood cancers, 331–338 female reproductive cancers, 237–241 gastrointestinal tract tumors, 184–207 hepatobiliary cancers, 207–214 Hodgkin’s disease, 297, 299–301 lung cancer, 214–224 lymphatic and hematopoetic cancers, 282 multiple myleloma, 301–307 myelodysplastic syndromes, 326–331 non-Hodgkin’s lymphoma, 283, 288–296 oral, nasal, and laryngeal cancer, 179–184 skin cancer, 226–230 soft tissue sarcoma, 225 urologic cancers, 241–272 Carbamate interactions with other agents, 56–57 and AhR action, 56 cimetidine, 56 inhibitor SKF525A effects, 56 malathion coadministration, 56 phenobarbital, 56 acute human exposure, 52–53 carcinogenicity, 54 chemical structure of, 51 chemistry of, 51 developmental effects, 54–55 experimental data on, 53–55 genetic polymorphisms and susceptibility, 52 genotoxicity, 54 immune function changes, 55 immunosuppression, 55 interactions with other agents, 56–57 lysozyme activity changes, 55 mechanism of action, 52 mutagenicity, 54 neurotoxic effects, 53–54 reproductive effects, 54–55 serum complement-fixing activity changes, 55 toxicokinetics, 51–52 chemical structure of, 51 sperm and semen parameters and, 455 Carboxylesterase, interactions with organophosphorous compounds, 50 Carcinogenicity of carbamates, 54 of lindane, 65 of organophosphorous compounds, 47–48
|
|
|||||||||||||||
